{"entity":{"id":"dalteparin","kind":"drug","name":"Dalteparin","aka":["dalteparin sodium"],"tldr":"Dalteparin is a daily blood-thinning injection. Its US label is one of the few written for people with cancer: it treats a clot and keeps giving protection for six months so that another clot is less likely.","summary":"The Fragmin label includes \"extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer\", the therapy beginning with the initial treatment and continuing for six months, alongside DVT prophylaxis in surgery and in medical patients and the prevention of ischaemic complications of unstable angina. ITAC 2022 recommends LMWH for initial treatment and prefers LMWHs over vitamin K antagonists; dalteparin is the comparator in several of the trials ITAC weighs, including ADAM-VTE, where apixaban was compared with dalteparin. The NDA was first approved on 22 December 1994.","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Dalteparin","links":[{"label":"US label (DailyMed): Fragmin","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23527b8b-9b28-4e6d-9751-33b143975ac7"},{"label":"Farge et al., 2022 international clinical practice guidelines (ITAC) for the treatment and prophylaxis of venous thromboembolism in patients with cancer (Lancet Oncol 2022)","url":"https://doi.org/10.1016/S1470-2045(22)00160-7"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":["enoxaparin","tinzaparin","apixaban"],"cancers":[],"sections":[],"technologies":["cancer-associated-thrombosis"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["vte"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Fragmin","modality":"Low-molecular-weight heparin (injection)","supportive":true,"mechanism":"A low-molecular-weight heparin: potentiates antithrombin, mainly against activated factor X.","approvals":[{"region":"US","year":1994,"indication":"Extended treatment of symptomatic VTE to reduce recurrence in adults with cancer (six months); DVT prophylaxis; unstable angina; VTE in children","note":"Year is the original NDA 020287 approval (Drugs@FDA); the cancer indication came later"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/dalteparin/","neighbours":{"drug":[{"id":"apixaban","kind":"drug","name":"Apixaban","route":"/drugs/apixaban/"},{"id":"enoxaparin","kind":"drug","name":"Enoxaparin","route":"/drugs/enoxaparin/"},{"id":"tinzaparin","kind":"drug","name":"Tinzaparin","route":"/drugs/tinzaparin/"}],"technology":[{"id":"cancer-associated-thrombosis","kind":"technology","name":"Cancer-associated thrombosis prevention and treatment","route":"/technologies/cancer-associated-thrombosis/"}],"term":[{"id":"vte","kind":"term","name":"Venous thromboembolism (VTE)","route":"/terms/vte/"}]}}